An important progress in the treatment of ovarian cancer after 20 years

Česká verzia

Authors: Jindřich Fínek
Authors place of work: Onkologické a radioterapeutické oddělení a komplexní onkologické centrum FN Plzeň-Lochotín
Published in the journal: Prakt Gyn 2012; 16(2-4): 54-58
Category: Oncogynecology: Review Article

Summary

The paper presents a clear survey of trends in incidence and mortality for ovarian cancer, following from recent statistical data. It summarizes the present diagnostic possibilities, the used prognostic factors and treatment schemes. A special attention is given to treatment. The treatment of persistent or relapsing illness, where significant progress has been achieved during the past 20 years by introducing bevacizumab, a new drug used in combination with carboplatin and paclitaxel. This treatment scheme is indicated as initial treatment of an advanced (III B, III C and IV stages according to FIGO) ovarian epithelial cancer, Fallopian tube cancer or primary peritoneal cancer. This scheme is becoming a new standard of care of patients with an advanced ovarian cancer.

Key words:
bevacizumab – carboplatin – ovarian cancer – paclitaxel – GOG-0218 Study – ICON 7 Study

Zdroje

1. Vyzula R (ed). Modrá kniha České onkologické společnosti. 15. vyd. Brno: Česká onkologická společnost ČLS JEP 2012: C56–57. ISBN 978–80–904989–0-7. Dostupné i z WWW http://www.linkos.cz/informace-pro-praxi/modra‑kniha/9‑zhoubny‑novotvar-ovarii-a-tuby-c56–57.

2. Novotvary 2009. Praha ÚZIS ČR, NOR ČR 2012. ISSN 1210 857X. ISBN 978–80–7280–975–2. Dostupné i z WWW www.svod.cz.

3. Harter P, du Bois A, Hahmann M et al (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Committee; AGO Ovarian Cancer). Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial. Ann Surg Oncol 2006; 13(12): 1702–1710.

4. Burger RA, Brady MF, Bookman MA et al (Gynecologic Oncology Group). Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365(26): 2473–2483.

5. Burger RA, Brady MF, Bookman MA et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study. Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2010; 28(18 Suppl): Abstr. LBA1.

6. Morgan RJ, Alvarez RD, Armstrong DK et al. Ovarian Cancer, Version 3.2012. J Natl Compr Canc Netw 2012; 10(11): 1339–1349.

7. Vaughan S, Coward JI, Bast RC jr et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 2011; 11(10): 719–725.

8. Dostupné z WWW http://www.icon7trial.org.

9. Perren TJ, Swart AM, Pfisterer J et al (ICON7 Investigators). A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011; 365(26): 2484–2496.